Christian  Angermayer net worth and biography

Christian Angermayer Biography and Net Worth

Director of Atai Life Sciences

Christian Angermayer is an entrepreneur and investor and the founder of Apeiron Investment Group, his family office and merchant banking business. Apeiron focuses on Financial Services (especially fintech and crypto assets), Technology, Life Sciences, Media & Entertainment and Real Estate & Prop-Tech. Apeiron completes deals across the entire lifecycle and balance sheet of a company, from non-listed Seed/Start Up investments to larger scale Restructuring and Special Situations deals (mostly listed), and additionally also invests in venture and private equity funds.

In 2000, Christian co-founded Ribopharma (original patents for RNAi technology) which merged with stock market listed US SPAC Alnylam in 2003 and has a $13bn market cap today. Since then, Christian has created, co-founded and invested in numerous successful companies, has raised over $2bn for his portfolio companies and has been involved in more than 50 successful IPO- and M&A-transactions either as an entrepreneur, investor or banker/advisor.

Today, Christian is one of the most active and significant investors in European fintech companies with a special focus on crypto-currencies and blockchain-related business models. Apeiron’s cryptocurrency investments are mainly done via its subsidiary Cryptology Asset Group PLC. Among various other investments, Cryptology is the largest institutional shareholder of Block.One, the company behind EOS, one of the most successful protocol tokens.

With his biotech company atai Life Sciences, Christian has the ambitious goal to develop solutions for the more than 300 million people who suffer from depression, especially by bringing back formerly vilified drugs like psychedelics into the legal realm. With his biotech companies Rejuveron and Cambrian, Christian is developing drugs and technologies which have the potential to significantly prolong human life span and ultimately defeat death.

In addition to his entrepreneurial activities, Christian places great value on social, political and societal commitments. He is a Young Global Leader of the World Economic Forum, a member of the Presidential Advisory Council of His Excellency President Paul Kagame of Rwanda and a member of the Milken Institute Young Leaders Circle. Christian is a board member of Vienna-based Hayek Institute, a Libertarian and free-markets-focused think-tank and a member of The Court of the London School of Hygiene and Tropical Medicine.

Christian’s “Angermayer Policy and Innovation Forum” convenes several times a year Head of States, leading politicians, investors and scientists to discuss crucial topics and issues.

Passionate about the arts and film, Christian has (executive) produced 21 feature films including critically acclaimed movies like FilthAspern Papers and Hector And The Search For Happiness. He is the largest shareholder of DEAG, the largest live entertainment company in Europe, producing over 4,500 shows per year from pop to classic and from exhibitions to family entertainment. Christian has a unique art collection centred around the theme “Psychedelics / Entheogens”.

How old is Christian Angermayer?

Mr. Angermayer is currently 46 years old. There are 6 older executives and no younger executives at Atai Life Sciences. The oldest executive at Atai Life Sciences is Dr. Srinivas G. Rao M.D., Ph.D., Co-Founder & Co-CEO, who is 55 years old. Learn More on Christian Angermayer's age.

How do I contact Christian Angermayer?

The corporate mailing address for Mr. Angermayer and other Atai Life Sciences executives is c/o Mindspace Krausenstra sse 9-10, Berlin, Berlin 10117. Atai Life Sciences can also be reached via phone at 49-89-2153-9035 and via email at [email protected]. Learn More on Christian Angermayer's contact information.

Has Christian Angermayer been buying or selling shares of Atai Life Sciences?

Christian Angermayer has not been actively trading shares of Atai Life Sciences over the course of the past ninety days. Learn More on Christian Angermayer's trading history.

Who are Atai Life Sciences' active insiders?

Atai Life Sciences' insider roster includes Christian Angermayer (Director), Srinivas Rao (Insider), and Gregory Weaver (CFO). Learn More on Atai Life Sciences' active insiders.

Are insiders buying or selling shares of Atai Life Sciences?

During the last year, insiders at the sold shares 4 times. They sold a total of 2,900,353 shares worth more than $16,548,244.26. The most recent insider tranaction occured on September, 26th when Major Shareholder Life Sciences N.V. Atai sold 2,660,000 shares worth more than $16,093,000.00. Insiders at Atai Life Sciences own 31.2% of the company. Learn More about insider trades at Atai Life Sciences.

Information on this page was last updated on 9/26/2024.

Christian Angermayer Insider Trading History at Atai Life Sciences

See Full Table

Christian Angermayer Buying and Selling Activity at Atai Life Sciences

This chart shows Christian Angermayer's buying and selling at Atai Life Sciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Atai Life Sciences Company Overview

Atai Life Sciences logo
Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.
Read More

Today's Range

Now: $1.61
Low: $1.61
High: $1.61

50 Day Range

MA: $1.24
Low: $1.06
High: $1.73

2 Week Range

Now: $1.61
Low: $1.03
High: $2.85

Volume

7,376 shs

Average Volume

1,205,268 shs

Market Capitalization

$270.16 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.78